AddLife AB (FRA:1AD1) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1AD1 AddLife AB FRA:1AD1
87 GF Score
Price €14.67
GF Value €14.23
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is AddLife AB Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:1AD1
87GF Score
AddLife AB FRA:1AD1
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AddLife AB (FRA:1AD1) Overvalued in 2026?

Based on GuruFocus' analysis, AddLife AB stock appears to be overvalued. The current stock price of €14.67 is trading 3.1% above its estimated GF Value™ of €14.23. GuruFocus considers AddLife AB to be Fairly Valued.

Key valuation signals for FRA:1AD1:

  • Dividends Received:
  • GF Value™: €14.23 vs. price of €14.67 (3.1% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the FRA:1AD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AddLife AB Business Description

Address Brunkebergstorg 5, Box 3145, Stockholm, SWE, 103 62
AddLife AB is engaged in the business of providing products, services, and advisory services. The company operates in two segments: Labtech and Medtech. The Labtech segment provides analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical service to laboratories in medicine, research, academia and the food and pharmaceutical industries. The Medtech segment includes a range that spans from basic consumables to instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. The majority of revenue is derived from the Medtech segment.
87GF Score

Get the complete analysis for FRA:1AD1

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.67
Price
€14.23
GF Value